Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of the suitability of 19 pharmacogenomics biomarkers for individualized metformin therapy for type 2 diabetes patients.

Drug metabolism and personalized therapy - 30 Jun 2020

Xhakaza Lettilia, Abrahams-October Zainonesa, Pearce Brendon, Masilela Charity Mandisa, Adeniyi Oladele Vincent, Johnson Rabia, Ongole Joven Jebio, Benjeddou Mongi

Abstract excerpt

Objectives Type 2 Diabetes mellitus is a progressive metabolic disease characterized by relative insulin insufficiency and insulin resistance resulting in hyperglycemia. Despite the widespread use of metformin, there is considerable variation in treatment response; with approximately one-third of patients failing to achieve adequate glycemic control. Studies have reported the involvement of single nucleotide...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biomarkers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diabetes Mellitus, Type 2

Share to Glycated Hemoglobin

Share to Hypoglycemic Agents

Share to Metformin

Share to Pharmacogenetics

Share to Polymorphism, Single Nucleotide

Source

Identifiers

PMID: 32681778
DOI: 10.1515/dmpt-2020-0111

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of the suitability of 19 pharmacogenomics biomarkers for individualized metformin therapy for type 2 diabetes patients.PMID 32681778Read ↗

Identification of clinical and pharmacogenetic factors influencing metformin response in Type 2 diabetes mellitus.Semantic proximity Read ↗

A Review of the Impact of Pharmacogenetics and Metabolomics on the Efficacy of Metformin in Type 2 DiabetesSemantic proximity Read ↗

An Update on the Pharmacogenomics of Metformin: Progress, Problems and PotentialSemantic proximity Read ↗

Implications of genetic variations, differential gene expression, and allele-specific expression on metformin response in drug-naïve type 2 diabetes.Semantic proximity Read ↗

Impact of SLC22A1 variants rs622342 and rs72552763 on HbA1c and metformin plasmatic concentration levels in patients with type 2 diabetes mellitusSemantic proximity Read ↗

Metformin Pharmacogenomics: Current Status and Future DirectionsSemantic proximity Read ↗

The pharmacogenetics of metformin.Semantic proximity Read ↗

The influence of SLC22A3 rs543159 and rs1317652 genetic variants on metformin therapeutic efficacy in newly diagnosed patients with type 2 diabetes mellitus: 25 weeks follow-up study.Semantic proximity Read ↗

Pharmacogenetic impact of SLC22A1 gene variant rs628031 (G/A) in newly diagnosed Indian type 2 diabetes patients undergoing metformin monotherapy.Semantic proximity Read ↗

Pharmacogenetic studies update in type 2 diabetes mellitusSemantic proximity Read ↗

Pharmacogenetics and target identification in diabetes.Semantic proximity Read ↗

Personalized medicine in diabetes: the role of ‘omics’ and biomarkersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.